Loerop James has filed 45 insider transactions across 1 company since February 2024.
Most recent transaction: a grant/award of 97700 shares of Aclaris Therapeutics, Inc. ($ACRS) on February 02, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Restricted Stock Units | 97700 | $0.00 | 97,700.0000 | 122,564,741 | 9999.99% | 0.08% |
| Feb. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Employee Stock Option (Right to Buy) | 341900 | $0.00 | 341,900.0000 | 122,564,741 | 9999.99% | 0.28% |
| Feb. 3, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 20875 | $0.00 | 198,197.0000 | 122,564,741 | 11.77% | 0.02% |
| Feb. 3, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 20875 | $0.00 | 62,625.0000 | 122,564,741 | 25.00% | 0.02% |
| Feb. 3, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 5937 | $3.47 | 192,260.0000 | 122,564,741 | 3.00% | 0.00% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 14750 | $0.00 | 29,500.0000 | 122,564,741 | 33.33% | 0.01% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 11250 | $0.00 | 0.0000 | 122,564,741 | 100.00% | 0.01% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 10686 | $3.51 | 177,322.0000 | 122,564,741 | 5.68% | 0.01% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 14750 | $0.00 | 188,008.0000 | 122,564,741 | 8.51% | 0.01% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 7500 | $0.00 | 173,258.0000 | 122,564,741 | 4.52% | 0.01% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 11250 | $0.00 | 165,758.0000 | 122,564,741 | 7.28% | 0.01% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Resticted Stock Units | 7500 | $0.00 | 7,500.0000 | 122,564,741 | 50.00% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 15980 | $2.48 | 102,773.0000 | 77,296,665 | 13.46% | 0.02% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 15980 | $2.48 | 102,773.0000 | 77,296,665 | 13.46% | 0.02% |
| Dec. 31, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 73750 | $0.00 | 177,056.0000 | 122,619,311 | 71.39% | 0.06% |
| Dec. 31, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 33994 | $3.01 | 143,062.0000 | 122,619,311 | 19.20% | 0.03% |
| Jan. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 18150 | $0.00 | 161,212.0000 | 122,564,741 | 12.69% | 0.01% |
| Jan. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 18150 | $0.00 | 18,700.0000 | 122,564,741 | 49.25% | 0.01% |
| Dec. 31, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 73750 | $0.00 | 0.0000 | 122,619,311 | 100.00% | 0.06% |
| Jan. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 6171 | $2.88 | 155,041.0000 | 122,564,741 | 3.83% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 11250 | $0.00 | 11,250.0000 | 77,296,665 | 50.00% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 11250 | $0.00 | 96,503.0000 | 77,296,665 | 13.20% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 7500 | $0.00 | 104,003.0000 | 77,296,665 | 7.77% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 14750 | $0.00 | 118,753.0000 | 77,296,665 | 14.18% | 0.02% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 15447 | $2.48 | 103,306.0000 | 77,296,665 | 13.01% | 0.02% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Resticted Stock Units | 7500 | $0.00 | 15,000.0000 | 77,296,665 | 33.33% | 0.01% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 14750 | $0.00 | 44,250.0000 | 77,296,665 | 25.00% | 0.02% |
| Feb. 3, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Restricted Stock Units | 83500 | $0.00 | 83,500.0000 | 77,296,665 | 9999.99% | 0.11% |
| Feb. 3, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Employee Stock Option (Right to Buy) | 292300 | $0.00 | 292,300.0000 | 77,296,665 | 9999.99% | 0.38% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 18150 | $0.00 | 36,850.0000 | 77,296,665 | 33.00% | 0.02% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Restricted Stock Units | 55000 | $0.00 | 55,000.0000 | 77,296,665 | 9999.99% | 0.07% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 73750 | $0.00 | 73,750.0000 | 71,381,731 | 50.00% | 0.10% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 8575 | $2.48 | 85,253.0000 | 77,296,665 | 9.14% | 0.01% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 18150 | $0.00 | 93,828.0000 | 77,296,665 | 23.98% | 0.02% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 32089 | $2.48 | 75,678.0000 | 71,381,731 | 29.78% | 0.04% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 73750 | $0.00 | 107,767.0000 | 71,381,731 | 216.80% | 0.10% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 3853 | $1.20 | 29,085.0000 | 69,808,855 | 11.70% | 0.01% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Restricted Stock Units | 147500 | $0.00 | 147,500.0000 | 69,808,855 | 9999.99% | 0.21% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 11250 | $0.00 | 32,938.0000 | 69,808,855 | 51.87% | 0.02% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Restricted Stock Units | 59000 | $0.00 | 59,000.0000 | 69,808,855 | 9999.99% | 0.08% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | A | Employee Stock Option (Right to Buy) | 206500 | $0.00 | 206,500.0000 | 69,808,855 | 9999.99% | 0.30% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Unit | 7500 | $0.00 | 22,500.0000 | 69,808,855 | 25.00% | 0.01% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Restricted Stock Units | 11250 | $0.00 | 22,500.0000 | 69,808,855 | 33.33% | 0.02% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | F | Common Stock | 2568 | $1.20 | 34,017.0000 | 69,808,855 | 7.02% | 0.00% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Loerop James | Chief Business Officer | M | Common Stock | 7500 | $0.00 | 36,585.0000 | 69,808,855 | 25.79% | 0.01% |